Myosin Therapeutics is a clinical-stage oncology and neuroscience company developing first-in-class therapies targeting cancer cell mechanics, the physical machinery tumors use to move, adapt, and divide under therapeutic stress, and maladaptive brain plasticity in substance use disorders. MT-125, the lead program, is a brain-penetrant dual non-muscle myosin II (NMIIA/IIB) inhibitor designed to induce mechanical failure, tumor cell death, and synergy with radiation. The ongoing Phase 1/2 STAR-GBM study (NCT07185880) is evaluating MT-125 with standard radiotherapy in newly diagnosed glioblastoma. The oncology pipeline also includes planned programs in Acute Myeloid Leukemia (AML) and Pancreatic Ductal Adenocarcinoma (PDAC), supported by compelling preclinical sensitivity data. IND-enabling studies are underway for MT-110, a selective NMIIB inhibitor intended to reset aberrant neural plasticity driving substance use disorders.